RLMD
Relmada Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.88
+0.28 (+7.78%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| EPS | — | — | — |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| Rev Growth | +24.2% | +0.2% | +22.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 97.84M | 116.11M | 118.62M |
| Total Equity | 123.72M | 117.70M | 119.20M |
| D/E Ratio | 0.79 | 0.99 | 1.00 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |